Profitelligence Profitelligence · Filing Ledger Open ABBV research →

Form 8-K · Current Report · Filed 2025-02-14

AbbVie Elects CEO as New Chairman

AbbVie Inc. announced on February 13, 2025, that its Board of Directors elected CEO Robert A. Michael as the new Chairman, effective July 1, 2025. Richard A. Gonzalez, the current Chairman, will retire on the same date. Additionally, Glenn F. Tilton will retire from the board. The changes were disclosed in a press release on February 14, 2025.

Filer
AbbVie Inc. ABBV · NYSE
Filed
Accession
0001104659-25-013467
CIK
0001551152
Signal
High impactHealthcare

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Board Member Departure New CEO Appointed
Item 7.01

Regulation FD Disclosure

Press Release Furnished
Item 9.01

Financial Statements and Exhibits

No viable tag

Market reaction

Close before filing

$193.45

Next session

+1.4%

Since filing

+29.7%

Latest close

$250.94

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from ABBV reporting the same item, with the next session's move:

Exhibits (1)

About AbbVie Inc.

AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another ABBV filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts